2-(4-Fluoro-Phenyl)-Thiazole-4-Carboxylic Acid Ethyl Ester

In the manufacture of an orally bioavailable, macrocyclic anaplastic lymphoma kinase (ALK) inhibitor assigned to a second-line non-small cell lung cancer (NSCLC) regimen, the ethyl ester of 2-(4-fluorophenyl)thiazole-4-carboxylic acid functions as a non-commodity late-stage intermediate that introduces both fluorine-mediated metabolic stability and a rigid thiazole spacer into the pharmacophore. The ester is not isolated as the free acid in the commercial synthesis; instead, a telescoped process is executed where saponification with 1.18±0.03 eq. of aqueous LiOH (2.5 M) in a 2000 L glass-lined reactor charged with THF/water (3.2:1 v/v) at a jacket temperature of 8–12 °C proceeds to >99 % conversion within 65 min, as monitored by inline ReactIR tracking the disappearance of the ester carbonyl at 1718 cm⁻¹. The resulting lithium carboxylate is acidified with 6 M HCl to pH 2.8–3.1 at 5 °C, filtered, and reslurried in ethyl acetate/n-heptane 1:4 to remove trace fluorobenzoic acid. The damp acid cake is then dissolved in anhydrous dimethylformamide (8 volumes relative to dry weight) and treated with O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU, 1.15 eq.) and N-methylmorpholine (2.7 eq.) at -8 °C before addition of the chiral amino-piperidine hydrochloride salt. The addition ratio—1.07 mol of the activated acid per mole of amine—compensates for the minor moisture ingress detected by Karl Fischer titration of the DMF solution (threshold ≤ 250 ppm H₂O). The amide coupling reaches completion after 14 h with a batch purity of 99.82 % by the in-process HPLC method (C18, 50 mM ammonium formate pH 3.2/acetonitrile gradient, UV 254 nm). Residual palladium from an earlier Suzuki step is controlled below 6 µg/g through a trimercaptotriazine-functionalised silica gel plug filtration; this level is validated against ICH Q3D Option 1 limits for oral drugs. The isolated penultimate amide is telescoped directly into a final reductive amination with 5.2 kg of sodium triacetoxyborohydride in dichloromethane to unmask the tertiary amine, yielding the API free base. After salt formation with methanesulfonic acid in acetone/water, the product is recrystallised from isopropanol to afford the mesylate salt with a polymorphic form matching that of the reference listed drug (confirmed by XRPD, PSD D90 < 35 µm). The final active pharmaceutical ingredient is compressed into 25 mg and 100 mg film-coated tablets under 21 CFR 211 GMP guidelines; dissolution testing per USP <711> apparatus 2 (paddle, 50 rpm, 0.1 M HCl) yields >85 % release in 30 min. Throughout the supply chain, the ethyl ester intermediate is qualified against ICH Q7 and carries a Certificate of Analysis documenting residual solvents per ICH Q3C (ethyl acetate < 4000 ppm, THF < 720 ppm) and absence of mutagenic impurities per ICH M7 based on a purge factor calculation.

Why does the ethyl ester require pre-activation via acid chloride before coupling with electron-deficient anilines?

When deployed as the central intermediate for a novel succinate dehydrogenase inhibitor (SDHI) fungicide active against Septoria tritici and Phakopsora pachyrhizi, direct amidation of the hydrolysed acid with 2-trifluoromethyl-4-chloroaniline proceeds sluggishly, delivering <10 % conversion after 24 h under standard HATU/DIPEA conditions. This is attributed to a combination of the aniline’s depressed nucleophilicity (conjugate acid pKa ~0.4) and the steric hindrance imposed by the ortho substituent. Consequently, the scaled process converts the free carboxylic acid—obtained via the same LiOH saponification described above but dried to a water content of <0.15 %—to the corresponding acid chloride using 1.5 eq. of thionyl chloride in toluene with 0.2 mol% DMF as catalyst. The mixture is heated to 50 °C over 45 min and held until off-gas evolution ceases (~4 h); excess thionyl chloride and solvent are stripped under reduced pressure at 40 °C jacket temperature to prevent thermal degradation. The crude acid chloride is dissolved in dichloromethane and added dropwise over 90 min to a chilled (0–5 °C) solution of the fluoroaniline and 1.2 eq. of triethylamine in the same solvent, utilizing a 50 L glass reactor with a turbidity probe to detect early precipitation of the triethylammonium chloride by-product. The amide product is isolated by aqueous workup and recrystallisation from ethanol/water 7:3, affording the penultimate SDHI core in 92 % yield with a differential scanning calorimetry purity of 99.1 % (melting point 161.3 °C). The title ester constitutes roughly 38–42 % of the total raw material cost in a multi-kilogram campaign and is used in a 1.00:0.98 molar stoichiometry relative to the aniline partner. Technical material manufactured via this route must satisfy FAO Specification 581/TC (for SDHI fungicide technical concentrates) with respect to minimum purity (≥ 98 %), water content (≤ 0.5 %), and acetone-insoluble matter. The commercial formulation—typically a 200 g/L emulsifiable concentrate (EC) featuring a calcium dodecylbenzenesulfonate/nonylphenol ethoxylate emulsifier pair, or a 500 g/kg water-dispersible granule (WG) extruded with lignosulfonate binder—undergoes toxicological assessment under 40 CFR Part 180 and EU Regulation (EC) No 396/2005 maximum residue level (MRL) compliance before registration. Field trials across the EU (BBCH 30–59) with a 150 g/ha application rate of the formulated SDHI, co-packed with a commercial triazole (125 g/L epoxiconazole), demonstrate curative activity, with the final product distributed as a 5 L HDPE jug.

Fluorinated thiazole photodecomposable amine generators (PAGs) that release a non-ionic sulfonic acid upon 193 nm exposure are built from the ethyl ester scaffold through a sequence of hydrazinolysis, cyclisation, and perfluoroalkylsulfonation. In a representative chemically amplified resist (CAR) formulation designed for sub-40 nm half-pitch line/space patterns under an NA 1.35 ArF immersion scanner, the functionalised derivative is dissolved in PGMEA together with a methacrylate-based copolymer (tertiary-butyl methacrylate/γ-butyrolactone methacrylate/adamantyl methacrylate 45:35:20 mol%). The active PAG derived from the ester typically accounts for 0.9–1.5 wt% of the total formulation weight; loadings above 2.5 wt% have been observed—through residual gas analysis on production-scale TEL Lithius Pro™ tracks—to induce T-top bridging due to excessive outgassing of perfluorobutanesulfonic acid fragments, as measured by quartz crystal microbalance (QCM) at a frequency shift exceeding 40 Hz. The PAG precursor is synthesised by first treating the ethyl ester with hydrazine hydrate (1.5 eq.) in ethanol at reflux for 6 h to obtain the hydrazide, which is subsequently acylated with perfluorobutanesulfonyl fluoride (1.8 eq.) in anhydrous THF containing polymer-bound 2,6-lutidine (3.0 eq.) to scavenge the liberated HF. The crude product is purified via automated flash chromatography (ethyl acetate/hexane 1:3, 40 µm silica gel) to an HPLC-ELSD purity of 99.5 %. The resist manufacturer operates under SEMI S2 environmental and safety guidelines and certifies the final product to RoHS Directive 2011/65/EU (lead-, mercury-, and cadmium-free); the outgoing resist lot must pass a laser-light scattering particle test (≥0.2 µm particles < 50 counts/mL). After filtration through a 0.02 µm PTFE membrane and nitrogen-blanketed packaging, the resist is supplied as 1 L light-shielded HDPE bottles qualified for point-of-use blending in 300 mm ArF immersion coats.

When the ester is converted into a veterinary coccidiostat precursor via a thiazolyl hydrazone condensation

A thiazole-triazine hybrid coccidiostat designed for the prophylaxis of Eimeria tenella in broiler chickens is accessed through a Knoevenagel-type condensation between the hydrazide derived from the title ester and 4-acetamidobenzaldehyde. The hydrazide is generated by refluxing the ethyl ester with 3.0 eq. of hydrazine monohydrate in ethanol (10 w/v) for 5 h; after cooling, the crystalline hydrazide is filtered and washed with cold methyl tert-butyl ether. Condensation with the aldehyde is run in absolute ethanol using 5 mol% piperidinium acetate at reflux (78 °C) for 14 h, and the resulting hydrazone is isolated by filtration at 0–5 °C with a yield of 87 %. The ester-derived building block accounts for approximately 24 % of the molecular mass of the final drug substance and is charged at a 1.05:1.00 molar ratio relative to the aldehyde component to drive the condensation beyond 97 % conversion. The hydrazone intermediate is then subjected to a triazine ring closure with cyanuric chloride (0.95 eq.) in dichloromethane/water biphasic medium at pH 8–9, controlled by automated dosing of 2 M sodium carbonate, yielding the N-substituted triazine scaffold. A final hydrogenation of the residual nitrile group under 15 bar hydrogen pressure over Raney Ni in a jacketed 1 L Hastelloy C-276 autoclave delivers the primary amine, which is immediately acylated with ethyl chloroformate (1.15 eq.) in THF at 10 °C to generate the carbamate prodrug. The entire synthesis is executed in a GMP pilot plant (ISO Class 10000 cleanroom) and the final veterinary premix must comply with VICH GL18 residual solvent limits, Commission Regulation (EU) No 37/2010 for maximum residue limits in poultry tissues, and manufacturing site registration under 21 CFR 225 for medicated feed additives. The formulated premix is a 0.5 % w/w microgranulated product blended onto calcium carbonate carrier and incorporated into complete feed at a rate of 1 kg/tonne of finished feed, providing a dose that suppresses oocyst shedding in floor-pen studies to < 5×10³ oocysts per gram of faeces.

[18F]Fluorobenzothiazole PET tracer precursors and automated radiochemistry

An emerging diagnostic application exploits the thiazole-4-carboxylate scaffold as a prosthetic group precursor for fluorine-18 radiolabeling, facilitating the preparation of a targeted positron emission tomography (PET) imaging agent for neuroinflammation. In this cassette-based radiochemistry workflow, 2–5 mg of the ethyl ester precursor—converted into the corresponding trimethylammonium triflate salt through quaternisation with methyl triflate and subsequent ion-exchange—is dissolved in anhydrous DMSO (0.8 mL) and loaded into a GE TRACERlab FX_FN module. Cyclotron-produced [¹⁸F]fluoride (37–111 GBq) is trapped on a QMA cartridge and eluted with a solution of K₂CO₃ (3.5 mg) and Kryptofix 2.2.2 (15 mg) in acetonitrile/water 4:1. After azeotropic drying under a stream of nitrogen at 100 °C and subsequent reconstitution in anhydrous acetonitrile, the activated [¹⁸F]fluoride is added to the precursor solution and heated at 85 °C for 15 min to effect nucleophilic aromatic substitution at the para-position of the fluorophenyl ring. The crude radiolabeled intermediate is purified by semi-preparative HPLC (Luna C18(2), 250 × 10 mm, 5 µm; mobile phase: 40 % v/v ethanol in water, flow rate 4 mL/min) with radiometric and UV (254 nm) detection. The collected fraction is diluted with water (50 mL) and passed through a C18 Sep-Pak to remove acetonitrile; the pure product is eluted with 1 mL of ethanol and formulated with 9 mL of 0.9 % saline to give a final ethanol content not exceeding 10 %. The quality control release panel, performed prior to patient administration, confirms radiochemical purity >98 % (radio-TLC and radio-HPLC), endotoxin levels < 5 EU/mL (USP <85>), residual Kryptofix < 50 µg/mL, and filter integrity by bubble-point test. All manufacturing steps adhere to 21 CFR 212 current good manufacturing practice for PET drugs, compendial sterility testing per USP <71> (initiated before release), and application-specific investigational new drug (IND) regulations. The final injectable dose is dispensed as a sterile, apyrogenic solution in a 15 mL Type I glass vial closed with a Teflon-coated stopper, ready for intravenous bolus administration at a typical activity of 185–370 MBq.